Detalhe da pesquisa
1.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
2.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657295
3.
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Oncologist
; 28(3): e167-e170, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576430
4.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(7): 888-898, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35688173
5.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
6.
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 26(5): 389-396, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33554383
7.
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
N Engl J Med
; 379(5): 417-427, 2018 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860937
8.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
9.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34364385
10.
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma.
J Natl Compr Canc Netw
; 19(4): 432-438, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33578374
11.
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.
Future Oncol
; 17(4): 403-409, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33028084
12.
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Lancet Oncol
; 21(1): 95-104, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31810797
13.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
14.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079938
15.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int
; 126(1): 73-82, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233107
16.
Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
Future Oncol
; 16(17): 1199-1210, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32363929
17.
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Lancet Oncol
; 20(2): 297-310, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30658932
18.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427204
19.
A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
Angiogenesis
; 22(3): 383-395, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739258
20.
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
Oncologist
; 24(3): 338-348, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30158285